X4 PHARMACEUTICALS INC

XFORNASDAQ

🏆 #2882 by market capEarnings Nov 4US Equity

$4.40▲ $0.12 (+2.69%)

Live

1h▲ 0.1%

24h▲ 2.7%

7d▲ 6.0%

14d▲ 9.9%

30d▲ 8.4%

1y▲ 70.3%

🏦Market Cap

$415M

Small Cap

📈Revenue Growth (YoY)

-71.3%

Declining

📊Gross Margin

81.8%

High

💵FCF Margin

—

⚖️P/S Ratio

48.6x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $4.33 – $4.43
52-Week Range: $1.35 – $4.83
Volume: $3.66B
Avg Volume: $3.80B
Shares Outstanding: 94.3M
Next Earnings: Oct 10, 2026

Fundamentals Snapshot

Annual Revenue: $35M
Last Q Revenue: $9M
P/E Ratio: —
P/S Ratio: 48.6x
EPS (TTM): $-4.58
Dividend Yield: —

Why Investors Own XFOR

✓High-growth profile — revenue up +30.8% YoY with expanding US Equity exposure.
✓Healthy economics — 38% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$35M▲ +34.5% YoY

Gross Margin (TTM)

37.9%▲ +4.5% YoY

Operating Income (TTM)

$3M▲ +34.5% YoY

Free Cash Flow (TTM)

$6M▲ +34.5% YoY

About X4 PHARMACEUTICALS INC

X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.

🦦